Methods
The PROTECTION cohort included retrospective data from 1,428 HIV patients treated with different TDF+PI combinations from 80 HIV clinics in Spain. We have performed a sub-analysis of those patients whose HAART regimens included at TDF in combinations including saquinavir (SQV) or fosamprenavir (FPV). Tables 1 and 2. The most prevalent adverse event was diarrhoea in the SQV cohort (11%) and hypertrigliceridaemia in the FPV cohort (4%). Only four patients (2%) withdrew their treatment due to an adverse event. One patient (0.5%) with baseline mild renal impairment (GFR: 63 mL/min) withdrew his treatment due to a grade 1 GFR decrease.
Summary of results

Conclusion
In this cohort, concomitant use of TDF with SQV or FPV was associated with good tolerability and an adequate rate of viral effectiveness, suggesting these combinations are suitable as rescue therapy in highly treatment-experienced patients. *In those subjects with 48 week data available (n = 36 and 26 for FPV and SQV cohorts, respectively).
